Literature DB >> 17996848

Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin.

Zhao Zheng1, Stefan Schwab, Armin Grau, Christian Berger.   

Abstract

Acetylsalicylic acid (ASA; Aspirin) has a neuroprotective potential by its anti-excitotoxic and anti-inflammatory effects. A temporary middle cerebral artery occlusion (tMCAO) model was used in 80 Wistar rats to evaluate whether a high dose of Aspirin (40 mg/kg) applied with different initiation time points after stroke onset (30 min, 3 h, 6 h, 12 h, 20 rats for each time group) and followed by repeated administration (1, 2 and 3 days) is neuroprotective. Neurological score and brain infarct volume were analyzed and indicated that postischemic therapy initiation at 30 min and as late as 6 h led to better neurological recovery (6 h, p=0.0046) and significant smaller infarct size (6 h, 57+/-9 mm(3), n=10, p=0.0043) compared to the saline control group (110+/-13 mm(3), n=10). Thus, there may be a relatively wide time window for acute stroke therapy with high dose Aspirin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17996848     DOI: 10.1016/j.brainres.2007.10.029

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  Strategies to defeat ketamine-induced neonatal brain injury.

Authors:  C P Turner; S Gutierrez; C Liu; L Miller; J Chou; B Finucane; A Carnes; J Kim; E Shing; T Haddad; A Phillips
Journal:  Neuroscience       Date:  2012-02-23       Impact factor: 3.590

2.  Targeting Neovascularization in Ischemic Retinopathy: Recent Advances.

Authors:  Mohamed Al-Shabrawey; Mohamed Elsherbiny; Julian Nussbaum; Amira Othman; Sylvia Megyerdi; Amany Tawfik
Journal:  Expert Rev Ophthalmol       Date:  2013-06

3.  Aspirin upregulates the expression of neuregulin 1 and survivin after focal cerebral ischemia/reperfusion in rats.

Authors:  Fan He; Fang Qu; Fulin Song
Journal:  Exp Ther Med       Date:  2012-01-12       Impact factor: 2.447

4.  Combination treatment with ethyl pyruvate and aspirin enhances neuroprotection in the postischemic brain.

Authors:  Seung-Woo Kim; Ji-Young Jeong; Hyun Ji Kim; Ji-Seon Seo; Pyung-Lim Han; Sung-Hwa Yoon; Ja-Kyeong Lee
Journal:  Neurotox Res       Date:  2009-07-28       Impact factor: 3.911

Review 5.  Multifunctional actions of approved and candidate stroke drugs.

Authors:  Jens Minnerup; Wolf-Rüdiger Schäbitz
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

6.  Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.

Authors:  Hans-Christoph Diener; Ralph L Sacco; Salim Yusuf; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  Lancet Neurol       Date:  2008-08-29       Impact factor: 44.182

7.  Selective inhibition of ASIC1a confers functional and morphological neuroprotection following traumatic spinal cord injury.

Authors:  Liam M Koehn; Natassya M Noor; Qing Dong; Sing-Yan Er; Lachlan D Rash; Glenn F King; Katarzyna M Dziegielewska; Norman R Saunders; Mark D Habgood
Journal:  F1000Res       Date:  2016-07-26

8.  Infarct Volumes of Patients with Acute Ischemic Stroke Receiving Direct Oral Anticoagulants due to Non-Valvular Atrial Fibrillation.

Authors:  Nese G Yavasoglu; Yasemin Eren; Idil G Tatar; Irfan Yalcınkaya
Journal:  Ann Indian Acad Neurol       Date:  2021-02-09       Impact factor: 1.383

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.